New class of drugs may rival statins in lowering cholesterol

A new class of drugs, known as PCSK9 inhibitors, has demonstrated the ability to lower LDL cholesterol levels by 50% to 66% in a variety of patient groups, according to clinical trials sponsored by such companies as Amgen, Sanofi, Regeneron and Pfizer, and presented at the annual meeting of the American College of Cardiology. If approved, PCSK9 inhibitors would be the first new cholesterol treatment to reach the market since the appearance of statins 25 years ago. Clinical outcomes are still needed to show whether lowering LDL will result in a reduction of cardiovascular events, such as stroke and heart attack.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC